Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk

Associação entre o polimorfismo do gene metallopeptidase de matriz 9 e o risco de câncer de mama

Rogério Tadeu Felizi¹  Melissa Gonzalez Veiga¹  Ivo Carelli Filho¹  Ricardo Peres do Souto²  César Eduardo Fernandes¹  Emerson Oliveira¹

¹ Department of Gynecology, Faculty of Medicine of ABC, Santo André, SP, Brazil  ² Department of Biochemistry, Faculty of Medicine of ABC, Santo André, SP, Brazil

Address for correspondence Rogério Tadeu Felizi, MD, Av. Lauro Gomes, 2000, 09060-870, Vila Sacadura Cabral, Santo André, SP, Brazil (e-mail: rogerio.felizi@gmail.com).


Abstract

Objective Epidemiological studies have shown evidence of the effect of genetic variations in the pathogenesis of breast cancer and have suggested a relationship of the disease with genetic polymorphisms. Matrix metallopeptidase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and other essential extra cellular matrix components, being involved in the tumor cell invasion and metastasis. Our objective was to evaluate the relationship between the MMP-9-1562 C/T polymorphism (rs 3918242) and the risk of developing breast cancer.

Methods In this case-control study, the frequency of the MMP-9-1562 C/T polymorphism (rs 3918242) was determined in 148 women with breast cancer and 245 women without the disease. The DNA was extracted from plasma samples, and the gene was amplified by polymerase chain reaction (PCR); the presence of the polymorphism was determined using restriction enzymes.

Results After adjusting for confounding variables, we found that the polymorphism was not associated with the occurrence of breast cancer (odds ratio [OR] = 1.159, 95% confidence interval [CI]: 0.6625–1.997, p = 0.5964). We also found no association with more advanced disease, the presence of hormone receptors, human epidermal growth factor receptor 2 (HER2) overexpression, or rate of tumor cell proliferation.

Conclusion We did not observe a relationship between MMP-9-1562 C/T polymorphism (rs 3918242) and the occurrence of breast cancer.

Keywords ▶ MMP-9 metalloproteinase ▶ breast cancer ▶ genetic polymorphism ▶ genetics ▶ single-nucleotide polymorphisms

Resumo

Objetivo Estudos epidemiológicos vêm demonstrando evidências da influência de variações genéticas na patogênese do câncer de mama, e têm sugerido associação de polimorfismos com uma maior susceptibilidade à doença. A metallopeptidase de matriz 9 (MMP-9) é uma colagenase responsável pela degradação do colágeno tipo IV, o maior componente da membrana basal, e outros componentes essenciais da matriz extra
Introduction

Breast cancer is the most common type of cancer in the female population when disregarding cases of non-melanoma skin cancer. The mortality rate due to the disease presents an upward curve,1 contributing to make breast cancer a major public health problem and an important cause of mortality in adults.2 In 2018, 59,700 new cases were estimated in Brazil, representing an incidence rate of more than 56 cases per 100,000 women.3 Approximately 10 to 15% of breast cancer patients have a previous family history of the disease; however, only 5% can be explained by mutation of genes such as BRCA1 and BRCA2.3 Regarding family risk for the development of the disease, it is necessary to consider the influence of environmental factors and genetic variations that may alter the predisposition to the risk of breast cancer.4

Metalloproteinases (MMPs) are a family of endopeptidases participating in the degradation of extra cellular matrix and basement membrane barriers.5-7 Some members of the MMPs family have been shown to promote tumor growth, angiogenesis, invasion and metastasis in cancer patients.8-10 Matrix metalloproteinase 9 (MMP-9) is a collagenase responsible for the degradation of type IV collagen, the major component of the basement membrane, and others essential extra cellular matrix components, being involved in the tumor cell invasion and metastasis.11,12

The gene MMP-9 is located on chromosome region 20q11.2-q13.1.13 Genetic variation may alter MMP-9 expression, influencing breast cancer susceptibility.14 Differential expression of MMP-9 reflects the degree of differentiation of breast cancer cells and that its overexpression is closely related with the most aggressive subtypes.15

Several single-nucleotide polymorphisms (SNPs) have been reported to be correlated with tumor progression and worse disease prognosis. Among MMP-9 polymorphisms, 1562 C/T (rs 3918242), a C to T substitution at −1562 bp, is the most studied.14 Researches have been performed to confirm the relationship between the pointed polymorphism and breast cancer susceptibility, however results are inconclusive.14

In this clinical, cross-sectional case-control study, we evaluated the potential relationship of the MMP-9 gene polymorphism with breast cancer and aggressiveness of the disease.

Methods

We studied 393 women, recruited between 2013 and 2015, who were followed up in the mastology sector of the division of gynecology of the Faculdade de Medicina do ABC (FMABC). The participants were divided into two groups: 148 with histologically confirmed diagnosis of breast cancer (case group) and 245 without the disease, with normal clinical and mammographic examinations (control group). For the patients with breast cancer, staging of the disease was retrieved from the patients’ records, based on the tumor, node and metastasis (TNM) classification of malignant tumors. Immunohistochemical analysis of the tumor was performed to determine the presence of estrogen receptors (detected using the EP1 clone), human epidermal growth factor receptor 2 (HER2) overexpression and Ki67. Tumors exhibiting at least 1% of tumor cells staining for estrogen receptor were considered positive. Breast cancers were tested for HER2 overexpression by immunohistochemistry (IHC), and cases showing equivocal (2+) staining by IHC required reflex testing by HHER2 D-FISH. The Ki67 cut-off was considered 25%. Clinical data were collected with the use of a questionnaire; the following data were recorded: age, age at menarche and last menstruation, number of pregnancies, previous use of hormonal medications, breastfeeding, history of smoking, alcohol consumption and endocrine diseases. The patients included were informed about the study and signed a consent form.
Venous blood samples were collected from women of both groups, and genomic DNA was extracted using the Illustra blood genomic prep mini spin reagent kit (GE Healthcare, Chicago, IL, USA), following the manufacturer's instructions. The presence of the MMP-9 polymorphism was determined following the PCR-RFLP procedure described by Zhang et al (1999). For the amplification of the promoter region of the gene by polymerase chain reaction (PCR), the following primers were used: 5′-GCC TGG CAC GTA GGC CC-3′ e 5′- C TT CCT AGC CAG CCG GCA TC-3′. The 435-bp PCR products were treated with the Sphl restriction enzyme, and the restriction fragments were separated by electrophoresis in 2.5% agarose stained with ethidium bromide. At the end of the analysis, C/C homozygotes should present a single 435-bp band, T/T homozygotes should present two bands of 247 and 188 bp, and T/C heterozygotes should present three bands of 435, 247 and 188 bp.

To assess the association between the study groups and the categorical variables, we used the frequency chi-squared test, whereas the continuous variables were analyzed using the unpaired t-test. The Hardy-Weinberg equilibrium was also tested using the chi-squared test. After the stratification of the groups, the effect of the MMP-9 polymorphism on breast cancer development was estimated by the odds ratio (OR), obtained by the binary logistic regression model, using the SPSS software, version 23.0 (IBM Corp., Armonk, NY, USA). The confidence interval adopted was 95% (95%CI), and the value for rejection of the null hypothesis was set at 0.05 or 5% (α ≤ 0.05).

The project was approved by the Research Ethics Committee of the institution under number 169/2010.

**Results**

A total of 148 women were included in the case group, and 245 women were included in the control group. The clinical and epidemiological characteristics of both groups are described in Table 1. Both groups presented homogeneity for almost all of the characteristics evaluated, with similar proportions of women over 50 years of age, menopausal women and/or women who used hormone therapy in the case and control groups. The variable parity and the age at first pregnancy also showed no significant differences between the groups. Cases were more likely to use oral contraceptives than controls, with frequency of use at 22.3% and 6.1%, respectively (p < 0.0001). The family history of breast cancer (p = 0.04) was more frequent in women who presented with the disease, with a difference of almost 10% between the groups.

Genotyping and frequency of the alleles are described in Table 2. The distribution of the genotypes is in genetic equilibrium according to the Hardy-Weinberg principle in the case and control groups.

Due to the low incidence of the TT genotype in the studied population, we chose to analyze the results comparing the wild homozygous group (CC) with the polymorphic group (TC + TT). After adjusting for oral contraceptive use and family history of breast cancer, the presence of the T allele and the TT (TC + TT) genotype of the MMP-9 polymorphism was not directly associated with tumor occurrence (OR = 1.159, 95% CI: 0.6625–1.997, p = 0.5964). In addition, no statistically significant difference was found between the polymorphisms when analyzing according to the staging of the disease, estrogen receptor status, HER2 overexpression or non-overexpression, or cell proliferation rate represented by Ki67, as shown in Table 3.

**Discussion**

Hereditary predisposition to breast cancer significantly influences the screening and follow-up of women at high risk for developing the disease, enabling early diagnosis, personalized conduct and family counseling. However, in patients with a personal or family history of breast cancer, a specific genetic predisposition is identified in less than 30% of cases. Thus, it seems that the effect of low-penetration gene polymorphisms on the risk for breast cancer is relevant only in polygenic forms.

Studies have demonstrated that degradation of extracellular matrix and basement membrane by MMPs play an
important role in tumorigenesis by modulating cell proliferation, apoptosis, tumor invasion and metastasis.18 The role played by MMP-9 in the malignancy and the growth of the tumor is an important one.14

Numerous single-nucleotide polymorphisms (SNPs) have already been identified in the MMP-9 gene, and the most common variant is 1562 C/T (rs 3918242). Our study demonstrated that the T allele and the TT genotype of the MMP-9 polymorphism were not directly associated with the occurrence of breast cancer, as shown in Table 2.

The association between this polymorphism and the disease has already been studied by groups from several countries, without a direct relationship being established. An Indian study revealed that the frequency of T-allele of MMP-9−1562 C/T promoter polymorphism was found to be predominant in breast cancer group compared with controls, with a 1.44 folds increased risk for breast cancer.19 Merdad et al20 showed that MMP-9 is a reliable potential candidate diagnostic biomarker and drug target in breast cancer. An Iranian study,18 published in 2015, found association between higher risk of developing breast cancer and MMP-9 polymorphism, as the presence of mutant allele increased the susceptibility to the disease by 1.87 times (OR = 1.87, IC95: 1.05–3.33, p = 0.035). Similarly, a large meta-analysis,7 also from 2015, showed an association between TT genotype of MMP-9−1562 C/T polymorphism and a higher risk for breast cancer. This result was in contrast to our study, which was supported by a South Brazilian research (p = 0.23).21 and a meta-analysis conducted by Zhou et al,22 which involved more than 5,000 patients. Both studies found no evidence that the 1562 C/T polymorphism (rs3918242) is correlated with a higher risk for breast cancer.

Several studies have described the role of MMPs in breast cancer progression and metastasis development, as MMPs are involved in the degradation of basement membranes.23 In a meta-analysis24 including more than 10,000 cancer cases, MMP-9 (1562 C/T) was shown to increase the risk of cancer metastasis, correlating the polymorphism with a more aggressive disease (OR = 1.25, IC95: 1.03 – 1.51, p = 0.07). Our results were inconsistent with this finding, as the adjustment for disease stage did not involve a higher frequency of polymorphism in more advanced tumors (p = 0.4075).

A factor with strong involvement that has not yet been established as a risk factor is the use of oral contraceptive, which, in our study, was related to higher occurrence of the disease (p < 0.0001).25 A meta-analysis26 correlating Iranian studies demonstrated that the use of oral contraceptives may stimulate the occurrence of breast cancer because it directly increases estrogen levels and indirectly influences weight gain. Our finding is consistent with the results reported in an analysis27 published in 2016, which showed an OR of breast cancer development that was 54.6% lower in patients who did not use oral contraceptives compared with those who used it.

Approximately 5 to 10% of breast cancer cases are familial and occur earlier than those in the general population. The BRCA1 and BRCA2 mutations are primarily responsible for hereditary breast cancer.28 Despite years of research, it has been shown that a minority of patients with a personal or family history of breast cancer have a genetic mutation as an identifiable cause.17 Our study is consistent with the global literature, as we found a positive association of family history with development of the disease (p = 0.004).

Stratified analysis according to HER2 or estrogen receptor expression in neoplastic cells showed no relationship with the occurrence of the polymorphism studied, and similarly, Ki67—a tumor cell proliferation index—was not a factor associated with the greater presence of the polymorphic alleles. We believe, however, that more studies are needed to confirm any of the proposed hypotheses due to the lack of evidence in the literature on the subject.

### Conclusion

The main results of this study suggest that the T allele and the TT genotype of 1562 C/T (rs 3918242) of the MMP-9 do not play a key role in breast cancer development. Although research has been performed to explore the role of SNPs of this gene in breast cancer, the results are inconclusive. We note that the controversy remains over the influence of 1562 C/T (rs 3918242) of the MMP-9 on the genesis of breast cancer. More studies and a larger case sample are necessary to confirm the effects on the risk of breast cancer to assist in the screening and follow-up of patients at increased risk of the disease.

### Contributors

Felizi R. T., Veiga M. G., Carelli Filho I., Souto R. P., Fernandes C. E. and Oliveira E. contributed with the project and the interpretation of data, writing of the article, critical review of the intellectual content and final approval of the version to be published.

### Conflicts of Interest

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Table 3 Evaluation of matrix metallopeptidase 9 polymorphism and staging, status of estrogen receptor, HER2 and Ki67

<table>
<thead>
<tr>
<th>Staging</th>
<th>CC</th>
<th>TC + TT</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA−II B</td>
<td>90 (81%)</td>
<td>21 (19%)</td>
<td>0.4075</td>
</tr>
<tr>
<td>IIB−IV</td>
<td>25 (89%)</td>
<td>3 (11%)</td>
<td></td>
</tr>
<tr>
<td>Estrogen receptor +</td>
<td>86 (81.9%)</td>
<td>19 (18.1%)</td>
<td>0.796</td>
</tr>
<tr>
<td>Estrogen receptor -</td>
<td>29 (85.3%)</td>
<td>5 (14.7%)</td>
<td></td>
</tr>
<tr>
<td>HER2 +</td>
<td>21 (87.5%)</td>
<td>3 (12.5%)</td>
<td>0.766</td>
</tr>
<tr>
<td>HER2 -</td>
<td>94 (81.7%)</td>
<td>21 (18.3%)</td>
<td></td>
</tr>
<tr>
<td>Ki67 ≤ 25%</td>
<td>58 (85.3%)</td>
<td>10 (14.7%)</td>
<td>0.244</td>
</tr>
<tr>
<td>Ki67 &gt; 25%</td>
<td>41 (75.9%)</td>
<td>13 (24.1%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: HER2, human epidermal growth factor receptor 2. *Chi-squared test.
Acknowledgments
The authors would like to thank the patients for their contribution to the research, the anesthesiologist team of the services where the project was developed for the aid in collecting the material, and the interns of the Department of Biochemistry of FMABC for their dedication to the analysis of the material obtained.

References